Roche Holding AG’s Genentech unit informed that the corporation’s experimental drug ocrelizumab has issued promising and effective outcomes in the three late-stage studies against multiple sclerosis, potentially signaling a significant new treatment option for some distressing disease.
In each of the two studies that comprised a cluster of 1,656 patients with relapsing multiple sclerosis, the most common type of the condition, ocrelizumab proved superior to the generally used drug, Rebif. The result showed a decline in the annual rate of relapse of some key symptoms and other measures of the status of the disease, Roche said. Less than 10% of patients undergoes severe side effects on either drug, the company officials stated.
In the third trial that investigated 732 patients with primary progressive multiple sclerosis, the drug seemed more effective than a placebo in decreasing the growth of clinically disabling disease, as per the company. The degree of severe adverse events, counting serious infections was identical in each group— that measured slightly over 20%. It exhibited the first time a drug that is able to benefit in this more serious form of multiple sclerosis in a major trial, researchers commented.
Roche is yet to publish the full results from the studies, which were subsidized by Roche and its Genentech unit. Fallouts will be made accessible on Friday and Saturday in a meeting with the European Committee for Treatment and Research in Multiple Sclerosis, in Barcelona.
Over 400,000 Americans and 2.5 million people worldwide are inflicted with multiple sclerosis, an erratic and mysterious autoimmune disease that entails the central nervous system. Amid people who are suffering from the disease, the immune system of a body attacks the insulation, or myelin, close to the nerve cells that carries electric charges required to connect with other nerve cells.